Public preview. Funding rounds, founders, and growth signals require a free account.

Stingray Therapeutics, Inc.

Clinical-stage biotech developing ENPP1 inhibitors to activate the STING pathway for next-generation cancer immunotherapies.

Series ABiotechHouston, TX11-50 employees

Total raised

$12.7M

Last round

Option

$25K · May 2024

Stage

Series A

Status

Active

Founders & team

Co-founder, CEO

Co-founder, CTO

Head of Engineering

Head of Sales

🔒

Free account unlocks founder names, LinkedIn profiles, and prior companies.

Web traffic

Search interest

Social followers

Glassdoor rating

News mentions

Gov contracts

🔒

Free account unlocks 5 full profiles per day. Pro removes the limit.

Get notified the moment Stingray Therapeutics, Inc. files a new round, hires execs, or shows traction signals.

About this data

FlareSight surfaces funding data from SEC Form D filings within hours of submission. Browse our full startup funding database to find more recently funded companies.